Shh Pathway Inhibitor LDE225 (Sonidegib) Limits BCRP Activity and Decreases Topotecan Resistance in Monolayer and Spheroid Models of Ovarian Cancer

Resistance to topotecan (TOP) limits effectiveness of chemotherapy in recurrent ovarian cancer. Increased activity of ATP-binding cassette (ABC) transporters, including breast cancer resistance protein (BCRP), is one of the mechanisms implicated in the development of TOP resistance. LDE225 (Sonidegib), a Smoothened (SMO) inhibitor targeting the Sonic Hedgehog pathway, has demonstrated antitumor properties, but its activity in TOP-resistant ovarian cancer remains insufficiently characterized. Here, we investigated LDE225 in A2780 ovarian cancer cells and their TOP-resistant, BCRP-overexpressing sublines using two-dimensional (2D) and three-dimensional (3D) models, which are relevant settings for investigating BCRP-associated TOP resistance in ovarian cancer. LDE225 reduced cell proliferation, colony formation, and migration in both TOP-sensitive and TOP-resistant cells. It also exhibited TOP-independent cytotoxicity and restored TOP sensitivity in resistant cells in both culture models. Although LDE225 did not reduce BCRP expression, fluorescence microscopy and flow cytometry demonstrated decreased transporter activity following treatment. Collectively, these findings demonstrate that LDE225 affects several phenotypic features of ovarian cancer cells and may be associated with the restoration of TOP sensitivity in resistant cells. Reduced BCRP activity may contribute to this effect, although the underlying mechanism requires further investigation. These findings support further evaluation of LDE225 as a single agent or in combination with TOP in TOP-resistant ovarian cancer.

Authors

Institutions

Publication Details

Journal
Cells
Published
2026-11-13
DOI
https://doi.org/10.3390/cells15222075
Primary Topic
Drug Transport and Resistance Mechanisms
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Shh Pathway Inhibitor LDE225 (Sonidegib) Limits BCRP Activity and Decreases Topotecan Resistance in Monolayer and Spheroid Models of Ovarian Cancer

Jan Korbecki, Monika Świerczewska, Julia Maria Lipowicz, Piotr Stasiak et al.
3 links
Cells
Drug Transport and Resistance Mechanisms
article

Shh Pathway Inhibitor LDE225 (Sonidegib) Limits BCRP Activity and Decreases Topotecan Resistance in Monolayer and Spheroid Models of Ovarian Cancer

Jan Korbecki, Monika Świerczewska, Julia Maria Lipowicz, Piotr Stasiak, Agnieszka Anna Rawłuszko-Wieczorek, Radosław Januchowski, Karolina Sterzyńska, Artur Płóciennik, Justyna Sopel
article en

Abstract

Resistance to topotecan (TOP) limits effectiveness of chemotherapy in recurrent ovarian cancer. Increased activity of ATP-binding cassette (ABC) transporters, including breast cancer resistance protein (BCRP), is one of the mechanisms implicated in the development of TOP resistance. LDE225 (Sonidegib), a Smoothened (SMO) inhibitor targeting the Sonic Hedgehog pathway, has demonstrated antitumor properties, but its activity in TOP-resistant ovarian cancer remains insufficiently characterized. Here, we investigated LDE225 in A2780 ovarian cancer cells and their TOP-resistant, BCRP-overexpressing sublines using two-dimensional (2D) and three-dimensional (3D) models, which are relevant settings for investigating BCRP-associated TOP resistance in ovarian cancer. LDE225 reduced cell proliferation, colony formation, and migration in both TOP-sensitive and TOP-resistant cells. It also exhibited TOP-independent cytotoxicity and restored TOP sensitivity in resistant cells in both culture models. Although LDE225 did not reduce BCRP expression, fluorescence microscopy and flow cytometry demonstrated decreased transporter activity following treatment. Collectively, these findings demonstrate that LDE225 affects several phenotypic features of ovarian cancer cells and may be associated with the restoration of TOP sensitivity in resistant cells. Reduced BCRP activity may contribute to this effect, although the underlying mechanism requires further investigation. These findings support further evaluation of LDE225 as a single agent or in combination with TOP in TOP-resistant ovarian cancer.

CellsVol. 15(22)
Poznan University of Medical Sciences (PL), University of Zielona Góra (PL)
Narodowym Centrum Nauki
Good health and well-being
Drug Transport and Resistance Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon